Literature DB >> 29057973

Revisiting GM-CSF as an adjuvant for therapeutic vaccines.

Weidong Zhao1, Gan Zhao, Bin Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29057973      PMCID： PMC5811680          DOI： 10.1038/cmi.2017.105

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  15 in total

1.  Update on castrate-resistant prostate cancer: 2010.

Authors:  Kiran Lassi; Nancy A Dawson
Journal:  Curr Opin Oncol       Date:  2010-05       Impact factor: 3.645

Review 2.  Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

Authors:  G Parmiani; C Castelli; L Pilla; M Santinami; M P Colombo; L Rivoltini
Journal:  Ann Oncol       Date:  2006-11-20       Impact factor: 32.976

3.  Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells.

Authors:  Honorio Torres-Aguilar; Sergio R Aguilar-Ruiz; Gabriela González-Pérez; Rosario Munguía; Sandra Bajaña; Marco A Meraz-Ríos; Carmen Sánchez-Torres
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

Review 4.  New generation adjuvants--from empiricism to rational design.

Authors:  Derek T O'Hagan; Christopher B Fox
Journal:  Vaccine       Date:  2015-06-08       Impact factor: 3.641

5.  A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Authors:  Gang Chen; Richa Gupta; Silvia Petrik; Marina Laiko; James M Leatherman; Justin M Asquith; Maithili M Daphtary; Elizabeth Garrett-Mayer; Nancy E Davidson; Kellie Hirt; Maureen Berg; Jennifer N Uram; Tianna Dauses; John Fetting; Elizabeth M Duus; Saadet Atay-Rosenthal; Xiaobu Ye; Antonio C Wolff; Vered Stearns; Elizabeth M Jaffee; Leisha A Emens
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

6.  Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

Authors:  Duane A Mitchell; Elias J Sayour; Elizabeth Reap; Robert Schmittling; Gabriel DeLeon; Pamela Norberg; Annick Desjardins; Allan H Friedman; Henry S Friedman; Gary Archer; John H Sampson
Journal:  Cancer Immunol Res       Date:  2014-11-11       Impact factor: 11.151

7.  Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.

Authors:  Xianzheng Wang; Aihua Dong; Jingjing Xiao; Xingjun Zhou; Haili Mi; Hanqian Xu; Jiming Zhang; Bin Wang
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

8.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Authors:  Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J Weinhold; Guido Ferrari; Scott D Parker; M Juliana McElrath; Sharon E Frey; Jonathan D Fuchs; Michael C Keefer; Michael D Lubeck; Michael Egan; Ralph Braun; John H Eldridge; Barton F Haynes; Lawrence Corey
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

9.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

10.  The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.

Authors:  Yong-tong Zhu; Zhen Zhao; Xin-yang Fu; Yang Luo; Cheng-yong Lei; Wei Chen; Fei Li; Shi-Yu Pang; San-San Chen; Wan-Long Tan
Journal:  Stem Cell Res       Date:  2014-04-24       Impact factor: 2.020
View more
  8 in total

Review 1.  Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.

Authors:  Ziyin Huang; Cassandra E Callmann; Shuya Wang; Matthew K Vasher; Michael Evangelopoulos; Sarah Hurst Petrosko; Chad A Mirkin
Journal:  ACS Cent Sci       Date:  2022-05-20       Impact factor: 18.728

2.  Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Authors:  Kimberly R Kalli; Matthew S Block; Pashtoon M Kasi; Courtney L Erskine; Timothy J Hobday; Allan Dietz; Douglas Padley; Michael P Gustafson; Barath Shreeder; Danell Puglisi-Knutson; Dan W Visscher; Toni K Mangskau; Glynn Wilson; Keith L Knutson
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

3.  Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID-19 Vaccines.

Authors:  Thibault Colombani; Loek J Eggermont; Zachary J Rogers; Lindsay G A McKay; Laura E Avena; Rebecca I Johnson; Nadia Storm; Anthony Griffiths; Sidi A Bencherif
Journal:  Adv Sci (Weinh)       Date:  2021-07-20       Impact factor: 16.806

Review 4.  Innate Lymphocytes in Inflammatory Arthritis.

Authors:  Xunyao Wu
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

Review 5.  Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.

Authors:  Maria Petrina; Jacqueline Martin; Sameh Basta
Journal:  Cytokine Growth Factor Rev       Date:  2021-01-09       Impact factor: 7.638

Review 6.  Research progress on dendritic cell vaccines in cancer immunotherapy.

Authors:  Jifeng Yu; Hao Sun; Weijie Cao; Yongping Song; Zhongxing Jiang
Journal:  Exp Hematol Oncol       Date:  2022-01-24

7.  Efficacy of a gB + gD-based subunit vaccine and the adjuvant granulocyte-macrophage colony stimulating factor for pseudorabies virus in rabbits.

Authors:  Zhi Cao; Ke Zhang; Heng Zhang; Hongliang Zhang; Ying Yu; Dehua Yin; Hu Shan; Zhihua Qin
Journal:  Front Microbiol       Date:  2022-08-03       Impact factor: 6.064

8.  Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis.

Authors:  Ninaad Lasrado; Arunakumar Gangaplara; Chandirasegaran Massilamany; Rajkumar Arumugam; Allison Shelbourn; Mahima T Rasquinha; Rakesh H Basavalingappa; Gustavo Delhon; Shi-Hua Xiang; Asit K Pattnaik; David Steffen; Jay Reddy
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.